Key Highlights
● AIM ImmunoTech says the last patient in its Phase 2 DURIPANC pancreatic-cancer study received a first Ampligen dose on June 18, 2026, with a clinical-benefit-rate readout targeted for early 2027, even as the company leans on repeated dilutive financings to fund operations.
● Per AIM's Form 10-Q for the quarter ended March 31, 2026, cash and equivalents were $5.8 million, up from $3.0 million at year-end 2025, after net cash used in operations of $2.7 million.
● Ampligen has been rejected by the FDA before, and none of AIM's current supportive data come from randomized, blinded, or multi-center trials; DURIPANC is a single-center, open-label study.
● Investors should watch for the DURIPANC clinical-benefit-rate readout targeted for early 2027.
AIM ImmunoTech Inc. (NYSE American: AIM), the Ocala, Florida-based developer of the experimental immunotherapy Ampligen (rintatolimod), said on June 18, 2026 that the final subject in its investigator-initiated Phase 2 DURIPANC trial had received a first dose of Ampligen combined with AstraZeneca's checkpoint inhibitor Imfinzi (durvalumab) for metastatic pancreatic cancer. Enrollment finished June 1, over a month ahead of the trial's original July target. The milestone caps a five-month stretch in which AIM also reported a 50% objective response rate in a separate, Merck-supported ovarian cancer study, resolved a stockholders'-equity deficiency that had put its NYSE American listing at risk, and raised roughly $8.5 million across four equity transactions. The clinical news is encouraging for a company whose lead drug has never won FDA approval; the financing pattern shows how thin its balance sheet remains.
What happened
The DURIPANC study, run at Erasmus Medical Center in the Netherlands, enrolls metastatic pancreatic cancer patients with stable disease after FOLFIRINOX chemotherapy, treating them with Ampligen plus durvalumab. Per the company's June 8 and June 18 releases, the trial is designed for up to 25 subjects, with a primary endpoint of Clinical Benefit Rate (CBR), stable disease, partial response, or complete response, assessed six months after treatment starts. CBR evaluation begins December 2026, with topline results expected in the first quarter of 2027; secondary endpoints, including overall and progression-free survival, begin analysis in June 2027. No interim efficacy or safety data from DURIPANC itself has been disclosed. Separately, a May 7, 2026 release on a UPMC-sponsored, Merck-supported Phase 2 trial combining intraperitoneal Ampligen, pembrolizumab, and intraperitoneal cisplatin in recurrent ovarian cancer reported a 50% objective response rate, 21% complete responses, a 79% clinical benefit rate, and median overall survival of 32.5 months, with no Grade 4 or 5 toxicities; secondary endpoint data are expected complete by January 2027.
Why the development matters
Full enrollment and dosing de-risk near-term execution for DURIPANC, AIM's furthest-along oncology program, and set a defined data timeline for the first time. The company has also cited historical Named Patient (compassionate-use) data, 57 subjects on Ampligen monotherapy showing median survival of 19.7 months versus 8.6 months in historical controls, widening to a 22.3-month improvement in a biomarker-defined subgroup, as rationale for a future Phase 3 study targeting "super-responder" patients. None of this comes from randomized, controlled trials, so it should be read as hypothesis-generating, not confirmatory.
Company and product background
Ampligen (rintatolimod) is a double-stranded RNA molecule activating toll-like receptor 3 to stimulate innate immune responses. It is not FDA-approved in the United States: the agency rejected Hemispherx Biopharma's (AIM's predecessor) new drug application for chronic fatigue syndrome in 2009, and a 2012 FDA advisory committee voted against approval on efficacy grounds. It is approved in Argentina for severe chronic fatigue syndrome and available in Canada and the Netherlands under named-patient access; it holds a recently finalized Japanese patent (March 18, 2026) covering combination use with checkpoint inhibitors. Beyond DURIPANC and the ovarian trial, AIM has explored Ampligen in long COVID, ME/CFS, and as a biodefense countermeasure, though none has a disclosed registration pathway.
Financial position
Per AIM's Form 10-Q for the quarter ended March 31, 2026, cash and equivalents were $5.8 million, up from $3.0 million at year-end 2025, after net cash used in operations of $2.7 million for the quarter (versus $2.4 million a year earlier). Stockholders' equity swung to a positive $2.1 million from a $9.8 million deficit at December 31, 2025, but common shares outstanding roughly tripled, to 8.2 million from 3.1 million, reflecting substantial dilution. Total notes payable stood near $4.2 million, including a roughly $1.68 million Streeterville Capital note later extended to June 30, 2027. The 10-Q disclosed substantial doubt about the company's ability to continue as a going concern and a NYSE American requirement to restore equity above $6.0 million by June 11, 2026. AIM subsequently raised roughly $2.4 million (May 20–21), $3.5–4.2 million via a warrant-exercise inducement (early May), and $2.65 million in an at-market offering priced at $0.5189 per share with warrant coverage for over 10 million more shares, a deal that coincided with a same-session stock decline reported by market outlets. NYSE American notified AIM on June 12, 2026 that the deficiency was resolved. Given roughly $2.7 million in quarterly cash burn, AIM's estimated runway likely covers only a few quarters absent further raises, an approximation, since no post-financing runway figure has been published.
Bull case
Bulls point to full, ahead-of-schedule enrollment and dosing in DURIPANC, encouraging (if uncontrolled) 50% ORR and 32.5-month survival figures from the ovarian trial, a patent position extending into Japan, and management's demonstrated ability to repeatedly access capital markets and resolve its listing deficiency. A positive CBR readout in early 2027, paired with biomarker data on likely responders, could support a Phase 3 design in a disease with few treatment options.
Risk case
Ampligen has been rejected by the FDA before, and none of AIM's current supportive data come from randomized, blinded, or multi-center trials, DURIPANC is a single-center, open-label study of up to 25 patients, and the survival comparisons rely on historical, not concurrent, controls. The going-concern disclosure, four separate financings within roughly two months, and a near-tripling of share count in a single quarter point to heavy, recurring dilution risk beyond the DURIPANC readout. Any delay to the December 2026/Q1 2027 timeline, or a disappointing CBR result, would remove a key catalyst.
What investors should watch next
1. DURIPANC Clinical Benefit Rate topline results, expected Q1 2027 (evaluation begins December 2026).
Conclusion
AIM ImmunoTech has hit a genuine operational milestone in dosing the final DURIPANC patient and produced intriguing, if preliminary, response and survival data in two small cancer trials. Those developments arrive alongside a financing cadence, four raises in roughly two months and a near-tripling of shares outstanding, that reflects how dependent the company remains on capital markets ahead of any regulatory milestone. Investors weighing the story should treat the clinical data as early and uncontrolled, and the funding picture as a live, ongoing variable.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.






Please wait processing your request...